Genomic Analysis of Mycobacterium tuberculosis Strains Resistant to Second-Line Anti-Tuberculosis Drugs in Lusaka, Zambia
Authors:
- Joseph Yamweka ChizimuJCJoseph Yamweka Chizimu
- Eddie Samuneti SoloESEddie Samuneti Solo
- Precious BwalyaPBPrecious Bwalya
- Thoko Flav KapalamulaTKThoko Flav Kapalamula
- Kaemba Kunkuta MwaleKMKaemba Kunkuta Mwale
- David SquarreDavid Squarre
- Misheck ShawaMSMisheck Shawa
- Patrick LunguPLPatrick Lungu
- David Atomanyi BarnesDavid Atomanyi Barnes
- Kaunda YambaKYKaunda Yamba
- Tiza MufuneTMTiza Mufune
- Herman ChambaroHCHerman Chambaro
Open Access
- 29 June 2023
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 12 (7) , 1126
Abstract
The emergence of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is a threat to TB control programs in developing countries such as Zambia. Studies in Zambia have applied molecular techniques to understand drug-resistance-associated mutations, circulating lineages and transmission patterns of multi-drug-resistant (MDR) Mycobacterium tuberculosis. However, none has reported genotypes and mutations associated with pre-XDR TB. This study characterized 63 drug-resistant M. tuberculosis strains from the University Teaching Hospital between 2018 and 2019 using targeted gene sequencing and conveniently selected 50 strains for whole genome sequencing. Sixty strains had resistance mutations associated to MDR, one polyresistant, and two rifampicin resistant. Among MDR strains, seven percent (4/60) had mutations associated with pre-XDR-TB. While four, one and nine strains had mutations associated with ethionamide, para-amino-salicylic acid and streptomycin resistances, respectively. All 50 strains belonged to lineage 4 with the predominant sub-lineage 4.3.4.2.1 (38%). Three of four pre-XDR strains belonged to sub-lineage 4.3.4.2.1. Sub-lineage 4.3.4.2.1 strains were less clustered when compared to sub-lineages L4.9.1 and L4.3.4.1 based on single nucleotide polymorphism differences. The finding that resistances to second-line drugs have emerged among MDR-TB is a threat to TB control. Hence, the study recommends a strengthened routine drug susceptibility testing for second-line TB drugs to stop the progression of pre-XDR to XDR-TB and improve patient treatment outcomes.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science, and Technology (JP23jk0210005, JP23jm0110021, JP23wm0125008, JP233fa627005, 22K0599902)
- Japan Agency for Medical Research and Development (AMED) (JP23jk0210005, JP23jm0110021, JP23wm0125008, JP233fa627005, 22K0599902)
- Japan Society for the Promotion of Science (JSPS) (JP23jk0210005, JP23jm0110021, JP23wm0125008, JP233fa627005, 22K0599902)
This publication has 46 references indexed in Scilit:
- Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational studyThe Lancet Infectious Diseases, 2013
- The immunological life cycle of tuberculosisNature Reviews Immunology, 2012
- Host–pathogen coevolution in human tuberculosisPhilosophical Transactions of the Royal Society B: Biological Sciences, 2012
- Old and New TB Drugs: Mechanisms of Action and Resistance2012
- A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering systemJournal of Antimicrobial Chemotherapy, 2012
- Prevalence of inappropriate tuberculosis treatment regimens: a systematic reviewEuropean Respiratory Journal, 2011
- Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10Journal of Antimicrobial Chemotherapy, 2011
- Fluoroquinolone Resistance among Mycobacterium tuberculosis Strains from Karachi, Pakistan: Data from Community-Based Field ClinicsAntimicrobial Agents and Chemotherapy, 2011
- Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, ZambiaBMC Infectious Diseases, 2010
- Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistanceJournal of Antimicrobial Chemotherapy, 2009